JP2023509421A - Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 - Google Patents

Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 Download PDF

Info

Publication number
JP2023509421A
JP2023509421A JP2022540327A JP2022540327A JP2023509421A JP 2023509421 A JP2023509421 A JP 2023509421A JP 2022540327 A JP2022540327 A JP 2022540327A JP 2022540327 A JP2022540327 A JP 2022540327A JP 2023509421 A JP2023509421 A JP 2023509421A
Authority
JP
Japan
Prior art keywords
independently selected
alkyl
group
optionally substituted
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
JP2022540327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509421A5 (https=
JPWO2021138419A5 (https=
Inventor
ウィリアム アール． ルーシュ
ハンス マルティン ザイデル
シャンカル ベンカトラマン
ジェーソン カッツ
Original Assignee
アイエフエム デュー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイエフエム デュー インコーポレイテッド filed Critical アイエフエム デュー インコーポレイテッド
Publication of JP2023509421A publication Critical patent/JP2023509421A/ja
Publication of JP2023509421A5 publication Critical patent/JP2023509421A5/ja
Publication of JPWO2021138419A5 publication Critical patent/JPWO2021138419A5/ja
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022540327A 2019-12-31 2020-12-30 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 Revoked JP2023509421A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962955853P 2019-12-31 2019-12-31
US62/955,853 2019-12-31
US202063090547P 2020-10-12 2020-10-12
US63/090,547 2020-12-10
PCT/US2020/067463 WO2021138419A1 (en) 2019-12-31 2020-12-30 Compounds and compositions for treating conditions associated with sting activity

Publications (3)

Publication Number Publication Date
JP2023509421A true JP2023509421A (ja) 2023-03-08
JP2023509421A5 JP2023509421A5 (https=) 2025-06-25
JPWO2021138419A5 JPWO2021138419A5 (https=) 2025-06-25

Family

ID=74550729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022540327A Revoked JP2023509421A (ja) 2019-12-31 2020-12-30 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Country Status (8)

Country Link
US (1) US20230115274A1 (https=)
EP (1) EP4085061A1 (https=)
JP (1) JP2023509421A (https=)
CN (1) CN115279770A (https=)
PY (1) PY2089151A (https=)
TW (1) TW202136255A (https=)
UY (1) UY39005A (https=)
WO (1) WO2021138419A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024502470A (ja) * 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112823036B (zh) 2018-07-03 2024-11-08 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
EP4267129A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
EP4267128A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
WO2022140397A1 (en) 2020-12-22 2022-06-30 Ifm Due, Inc. Methods of treating cancer
US20240060982A1 (en) 2020-12-22 2024-02-22 Ifm Due, Inc. Methods of treating cancer
TW202235073A (zh) 2021-01-08 2022-09-16 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
UY39892A (es) 2021-08-10 2023-03-31 Novartis Pharma Ag Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING
WO2024032597A1 (zh) * 2022-08-11 2024-02-15 杭州中美华东制药有限公司 具有sting抑制作用的酰胺类化合物及其药物组合物和用途
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
AU2023368953A1 (en) * 2022-10-28 2025-03-27 Boehringer Ingelheim International Gmbh Heterocyclic compounds as sting antagonists
CN117756698A (zh) * 2022-12-16 2024-03-26 中国药科大学 脲类化合物及其作为sting抑制剂的医药用途
CN116023321B (zh) * 2022-12-30 2024-11-29 中国药科大学 Sting抑制剂前药及其医药用途
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
US20250333398A1 (en) 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083005A1 (ja) * 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
JP2013545740A (ja) * 2010-11-10 2013-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしての置換された複素芳香族カルボキサミド誘導体および尿素誘導体
JP2014503574A (ja) * 2011-01-27 2014-02-13 ピエール、ファーブル、メディカマン 医薬としてのアザインダゾールまたはジアザインダゾール型の誘導体
WO2019201939A1 (en) * 2018-04-16 2019-10-24 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2012075380A1 (en) 2010-12-03 2012-06-07 The Trustees Of The University Of Pennsylvania Tip60 inhibitors
CN109394752A (zh) 2013-10-21 2019-03-01 德雷克塞尔大学 治疗慢性乙型肝炎病毒感染的sting激动剂的用途
CN112823036B (zh) * 2018-07-03 2024-11-08 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083005A1 (ja) * 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
JP2013545740A (ja) * 2010-11-10 2013-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしての置換された複素芳香族カルボキサミド誘導体および尿素誘導体
JP2014503574A (ja) * 2011-01-27 2014-02-13 ピエール、ファーブル、メディカマン 医薬としてのアザインダゾールまたはジアザインダゾール型の誘導体
WO2019201939A1 (en) * 2018-04-16 2019-10-24 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024502470A (ja) * 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Also Published As

Publication number Publication date
TW202136255A (zh) 2021-10-01
UY39005A (es) 2021-07-30
EP4085061A1 (en) 2022-11-09
US20230115274A1 (en) 2023-04-13
WO2021138419A1 (en) 2021-07-08
CN115279770A (zh) 2022-11-01
PY2089151A (es) 2022-05-11

Similar Documents

Publication Publication Date Title
JP2023509421A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP7756643B2 (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
TWI873145B (zh) 用於治療與sting活性相關之病狀的化合物及組合物
JP7566731B2 (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP7482122B2 (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2022535743A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2025066719A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2021067805A1 (en) Oxalamide heterobycyclic compounds and compositions for treating conditions associated with sting activity
JP2023540672A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2021067791A1 (en) Oxalamide compounds and compositions for treating conditions associated with sting activity
JP2023540673A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2024502474A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
JP2024502472A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2023554393A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2024263860A1 (en) Compounds and compositions for treating conditions associated with sting activity
JP2023540674A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2022015938A1 (en) Compounds and compositions for treating conditions associated with sting activity
JP2024502470A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2024151919A1 (en) Compounds and compositions for treating conditions associated with sting activity
JP2025503675A (ja) Ｓｔｉｎｇ活性に関連する病態を治療するための化合物及び組成物
JP2023554392A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2024502473A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するためのオキサルアミド化合物および組成物
JP2025504415A (ja) Ｓｔｉｎｇ活性に関連する病態を治療するための化合物及び組成物
JP2024532798A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231226

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20241018

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241025

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241210

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250307

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250327

A59 Written plea

Free format text: JAPANESE INTERMEDIATE CODE: A59

Effective date: 20250327

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250603

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250610

AA91 Notification that invitation to amend document was cancelled

Free format text: JAPANESE INTERMEDIATE CODE: A971091

Effective date: 20250617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260331